NCT04413344已完成1 期
Double-Blind Comparative Trial and Open-Label Extension Trial to Investigate the Safety and Efficacy of TW-012R in Alzheimer's Disease With Presenilin 1 (PSEN1) Mutations
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 8
- 主要终点
- Safety (Incidence and severity of adverse events and adverse reactions)
研究概览
简要总结
The goal of this clinical trial is to learn about safety and efficacy of bromocriptine in familial Alzheimer's disease with presenilin 1 mutations.
The main questions it aims to answer are: •safety of bromocriptine •efficacy of bromocriptine
Participants will answer questions, have blood exams, lumbar punctures and MRI/PET scans. Researchers will compare a participants group taking bromocriptine with a participants group taking placebo to see if there is any changes in cognitive function, and behavioral and psychiatric symptoms with dementia.
详细描述
To investigate the safety and efficacy of an orally administered dose of TW-012R in patients with Alzheimer's disease bearing PSEN1 (presenilin 1) mutations (PSEN1-AD), using a placebo group as a control. In addition, long-term safety will be examined in an open-label extension trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Alzheimer's disease patients with PSEN1 mutations
- •Patients diagnosed with "probable AD" according to the diagnostic guideline of NIA-AA or "probable Alzheimer-type dementia" according to the diagnostic criteria for Alzheimer's disease specified in DSM-5
- •An MMSE-J score of <= 25
- •Patients whose cognitive function and everyday function are obviously impaired based on their medical record or information provided by a person who knows the patient well
- •Patients for whom intellectual disability and mental disorders other than dementia can be ruled out based on their academic background, work history, and life history.
- •Patients with a reliable and close relationship with a partner/caregiver
- •Age>=20 years at the time of giving informed consent
- •Written informed consent has been obtained from the patient or his/her legally acceptable representative to participate in this trial
排除标准
- •Difficulty with the oral intake of tablets
- •Patients receiving anti-dementia drugs who have changed the dosing regimen during the 2 months prior to giving informed consent
- •Patients with dementia due to pathology other than Alzheimer's disease (e.g., vascular dementia, frontotemporal dementia, Lewy body dementia, progressive supranuclear palsy, corticobasal degeneration, Huntington's disease, and prion disease)
- •Presence of clinically relevant or unstable mental disorders. Patients with major depression in remission can be enrolled.
- •Imminent risk of self-harm or harm to others
- •Body mass index (BMI) of <= 17 or >= 35
- •Patients with a history of alcohol dependence, drug dependence, or drug abuse within the 5 years before providing informed consent
- •HBs antigen positive
- •Anti-HIV antibody positive
- •Anti-HTLV-1 antibody positive
- •Patients with an active infection, such as hepatitis C and syphilis (STS/TPHA)
- •Patients with the following liver function values on the test before enrollment
- •AST(GOT) > 4.0 x Upper limit of the institutional reference range or
- •ALT (GPT) > 4.0 x Upper limit of the institutional reference range
- •Patients who have uncontrolled, clinically significant medical conditions (e.g., diabetes melitus, hypertension, thyroid/endocrine disease, congestive cardiac failure, angina pectoris, cardiac/gastrointestinal disease, dialysis, and abnormal renal function with an estimated CLcr < 30 mL/min)within 3 months prior to giving informed consent in addition to the underlying disease to be investigated in the trial and for whom the investigator or sub-investigator considers that there is a significant medical risk in the patient's participation in the trial
- •Patients with long QT syndrome or tendency toward prolonged QTc interval (male: >=470 msec, female: >= 480 msec), or patients with a history/complication of torsades de pointes
- •Patients with a history of malignancies within 5 years prior to providing informed consent. However, patients with the following diseases can be enrolled if they are treated appropriately:
- •Skin cancer (basal cell, squamous cell)
- •Cervical carcinoma in situ
- •Localized prostate cancer
- •Malignancies that have not recurred for at least 3 years since surgery and the patient's physician has determined that the risk of recurrence is low
- •Patients with clinically significant vitamin B1/B12 deficiency or folic acid deficiency within 6 months prior to giving informed consent
- •Patients who have participated in other clinical research/trials involving interventions within the 3 months prior to providing informed consent
- •Patients who have previously received bromocriptine or TW-012R
- •Patients with a history of hypersensitivity to bromocriptine or ergot alkaloids
- •Patients with current or a history of thickened heart valve cusps, restricted heart valve motion, and the associated heart valve lesions, such as stenosis, confirmed by echocardiography
- •Pregnant females, lactating females, females who may be pregnant, and females who wish to become pregnant
- •Other patients who are considered inappropriate to participate in this trial at the discretion of the investigator or sub-investigator
研究组 & 干预措施
Active
Active Comparator
Bromocriptine mesilate, 2.5 to 22.5 mg per day, divided three times a day, for 50 weeks.
干预措施: Bromocriptine Mesilate (Drug)
Placebo
Placebo Comparator
Placebo, divided three times a day, for 50 weeks.
干预措施: Placebos (Drug)
结局指标
主要结局
Safety (Incidence and severity of adverse events and adverse reactions)
时间窗: Until Week 50 (end of trial)
to assess safety
Severe impairment battery-Japanese version (SIB-J)
时间窗: Until Week 20 and 36
to assess cognitive function
Neuropsychiatric Inventory (NPI)
时间窗: Until Week 20 and 36
to assess behavioral and psychiatric symptoms of dementia
次要结局
- Mental Function Impairment Scale (MENFIS)(Until Week 20 and 36)
- Disability Assessment for Dementia (DAD)(Until Week 20 and 36)
- Mini-Mental State Examination-Japanese (MMSE-J)(Until Week 20 and 36)
- Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III(Until Week 20 and 36)
- Apathy Scale(Until Week 20 and 36)
- Plasma Aβ protein concentration(Until Week 20 and 36)
- Plasma NfL protein concentration(Until Week 20 and 36)
- Plasma Total Tau, Plasma p-Tau concentration(Until Week 20 and 36)
- Cerebrospinal fluid (CSF) Aβ concentration(Until Week 36)
- CSF Total Tau, CSF p-Tau concentration(Until Week 36)
- Blood bromocriptine concentration(Until Week 20 and 36)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
1 期
Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersRespiratory Syncytial Virus InfectionsNCT01906164Alios Biopharma Inc.101
已完成
2 期
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or OxaliplatinColorectal CancerNCT00044343GlaxoSmithKline80
已完成
2 期
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.Neoplasms, BreastMetastatic Breast CancerNCT00051103GlaxoSmithKline
撤回
2 期
A Phase 2 Study With CC-220 in Skin SarcoidosisSarcoidosisNCT02192489Celgene
已完成
2 期
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeBipolar Disorder IBipolar Disorder IIMajor Depressive EpisodeNCT03692910Biogen35